The clinical use of colistin in patients with cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 6, 2001, Pages 434-440

  Beringer, Paul ^a,b   Shapiro, Bertrand J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; POLYPEPTIDE ANTIBIOTIC AGENT;

BACTERIAL COLONIZATION; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; REVIEW; SPIROMETRY;

EID: 0035169376     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200111000-00013     Document Type: Review

References (30)

1. Emergence of antibiotic resistance amongst P. aeruginosa isolates from patients with cystic fibrosis
2. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation
3. A ten year review of colomycin
4. Polymyxin B, colistin, and sodium colistimethate
5. 2+ environments
6. A reassessment of the in-vitro activity of colistin sulphomethate sodium
7. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas
8. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit
9. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria
10. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
11. Randomised UK/Eire clinical trial of the efficacy and safety of tobramycin 300mg/5ml nebulizer solution or nebulised colistin in CF patients
12. The pharmacokinetics of colistin in patients with cystic fibrosis
13. Advantages of colistin dry powder inhalation, proof of principle
14. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis
15. Bronchoconstriction following nebulised colistin in cystic fibrosis
16. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis
17. 28-day inhalation toxicology of polymyxin E1, the major active component of colistin, in rats and dogs
18. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis
19. Toxicity of colistin in cystic fibrosis patients
20. Camparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbations in cystic iibrosis
21. Adverse effects of sodium colistimethate, manifestations and specific reaction rates during 317 courses of therapy
22. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
23. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis
24. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
25. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
26. Antibiotic treatment of initial colonization with Pseudmonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
27. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation
28. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
29. Safety and effectiveness of 2 years of treatment with TOBI (tobramycin solution for inhalation) in CF patients
30. Something is (not) rotten in Denmark [Hamlet (Not) W Shakespeare]